AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8251960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Cost VideoConferencing System (LCVC)
Number of subjects: 0
Study 8251960 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face testing
Number of subjects: 0
Study 3311708 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 400
Study 3311708 — intervention group
Group type: COMPARATOR
Intervention: 24 hour continuous stimulation
Number of subjects: 400
Study 3311708 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 hours stimulation
Number of subjects: 400
Study 31906766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training with the Biodex Gait Trainer 3 (a treadmill integrated with music therapy)
Number of subjects: 40
Study 31906766 — intervention group
Group type: COMPARATOR
Intervention: Traditional over ground gait training (Control Group)
Number of subjects: 40
Study 29563779 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (500 mL·d‐1 for 1 month)
Number of subjects: 105
Study 29563779 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (500 mL·d‐1 for 3 months)
Number of subjects: 105
Study 29563779 — intervention group
Group type: COMPARATOR
Intervention: Control Group (free diet)
Number of subjects: 105
Study 26876716 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR4 antagonist
Number of subjects: 14
Study 26876716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 14
Study 26876716 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 25528251 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8% tranexamic acid
Number of subjects: 84
Study 25528251 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrin sponge
Number of subjects: 84
Study 25528251 — intervention group
Group type: COMPARATOR
Intervention: no local hemostatic agents
Number of subjects: 84
Study 24012915 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week exercise
Number of subjects: 0
Study 24012915 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 min/week exercise
Number of subjects: 0
Study 24012915 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/week exercise
Number of subjects: 0
Study 24012915 — intervention group
Group type: COMPARATOR
Intervention: Exercise recommendations
Number of subjects: 0
Study 21336125 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (RM) group (positive end‐expiratory pressure 15 cm H2O, peak inspiratory pressure 35‐40 cm H2O for 30 secs)
Number of subjects: 59
Study 21336125 — intervention group
Group type: COMPARATOR
Intervention: Non-recruitment maneuver (NRM) group (ventilation resumed without an RM)
Number of subjects: 59
Study 18849063 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intramuscular (IM) dimenhydrinate
Number of subjects: 86
Study 18849063 — intervention group
Group type: COMPARATOR
Intervention: 2 mL IM saline solution (placebo)
Number of subjects: 86
Study 17714332 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Mobility Task (GMT)
Number of subjects: 58
Study 17714332 — intervention group
Group type: COMPARATOR
Intervention: Clinical scales (UPDRS part III and Hoehn & Yahr's score)
Number of subjects: 58
Study 15054057 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome subjects
Number of subjects: 14
Study 11230840 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (high-dose groups)
Number of subjects: 48
Study 9489981 — intervention group
Group type: EXPERIMENTAL
Intervention: Center 1
Number of subjects: 99
Study 9489981 — intervention group
Group type: EXPERIMENTAL
Intervention: Center 2
Number of subjects: 99
Study 9489981 — intervention group
Group type: EXPERIMENTAL
Intervention: Center 3
Number of subjects: 99
Study 9489981 — intervention group
Group type: EXPERIMENTAL
Intervention: Center 4
Number of subjects: 99
Study 8565032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 30 mg
Number of subjects: 207
Study 8565032 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 207
Study 8565032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 60 mg
Number of subjects: 207
Study 8565032 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 207
Study 8565032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core
Number of subjects: 207
Study 8565032 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 207
Study 2350875 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg intravenously)
Number of subjects: 10
Study 2350875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 444346 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin and nitrous oxide in oxygen
Number of subjects: 170
Study 444346 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and nitrous oxide in oxygen and halothane
Number of subjects: 170
Study 30783173 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental feed
Number of subjects: 95
Study 30783173 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric feed
Number of subjects: 95
Study 30783173 — intervention group
Group type: COMPARATOR
Intervention: Standard feeds
Number of subjects: 95
Study 28938283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 88
Study 28938283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25851635 — intervention group
Group type: COMPARATOR
Intervention: Calcium citrate fasting
Number of subjects: 10
Study 25851635 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate with a meal
Number of subjects: 10
Study 25851635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified juice
Number of subjects: 10
Study 25851635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product meal
Number of subjects: 10
Study 26383579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed handpiece and minimally invasive extraction (Group A)
Number of subjects: 83
Study 26383579 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (Group B)
Number of subjects: 83
Study 24277399 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding group
Number of subjects: 70
Study 20835716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumoperitoneum (IPP)
Number of subjects: 51
Study 20835716 — intervention group
Group type: COMPARATOR
Intervention: Conventional conduct (CPP)
Number of subjects: 51
Study 18499623 — intervention group
Group type: EXPERIMENTAL
Intervention: PERI group receiving intraoperative and postoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Number of subjects: 81
Study 18499623 — intervention group
Group type: EXPERIMENTAL
Intervention: INTRA group receiving intraoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Number of subjects: 81
Study 18499623 — intervention group
Group type: COMPARATOR
Intervention: CTRL group receiving placebo
Number of subjects: 81
Study 16542203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg day(-1) and Olanzapine 15 mg day(-1) coadministration (LTG + OLZ group)
Number of subjects: 44
Study 16542203 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine 200 mg day(-1) with placebo (LTG group)
Number of subjects: 44
Study 16542203 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Olanzapine 15 mg day(-1) (OLZ group)
Number of subjects: 44
Study 12716329 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD) - Emdogain (U Biora AB Malm, Sweden)
Number of subjects: 98
Study 12716329 — intervention group
Group type: COMPARATOR
Intervention: Guided Tissue Regeneration (GTR) - ePTFE membranes (Gore‐Tex W.L. Gore and Associates, Flagstaff, AZ, USA)
Number of subjects: 98
Study 11113227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (0.7 mg/kg and 2.1 mg/kg)
Number of subjects: 159
Study 11113227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 9762661 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF oligoclonal IgG bands
Number of subjects: 27
Study 9762661 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific oligoclonal IgG antibodies
Number of subjects: 27
Study 9762661 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF Myelin Basic Protein-like material
Number of subjects: 27
Study 9762661 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF markers analysis
Number of subjects: 27
Study 2841177 — intervention group
Group type: EXPERIMENTAL
Intervention: White Bread (WB)
Number of subjects: 12
Study 2841177 — intervention group
Group type: EXPERIMENTAL
Intervention: French Toast (FT)
Number of subjects: 12
Study 2841177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran-Enriched French Toast (BFT)
Number of subjects: 12
Study 2841177 — intervention group
Group type: COMPARATOR
Intervention: Oral Glucose Load
Number of subjects: 12
Study 30511958 — intervention group
Group type: EXPERIMENTAL
Intervention: Twister wrap orthosis (TWO) in addition to conventional physical therapy and ankle foot orthosis (AFO)
Number of subjects: 30
Study 30511958 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy and ankle foot orthosis (AFO)
Number of subjects: 30
Study 26186485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) with 90% avoidance/10% approach for smoking stimuli and 10% avoidance/90% approach for neutral stimuli
Number of subjects: 60
Study 26186485 — intervention group
Group type: COMPARATOR
Intervention: Sham training with 50% avoidance/50% approach for smoking and neutral stimuli
Number of subjects: 60
Study 26186485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBM and sham
Number of subjects: 60
Study 24169284 — intervention group
Group type: EXPERIMENTAL
Intervention: Allitridi capsules (120 mg/day)
Number of subjects: 120
Study 24169284 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 21174182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic approach (MMA) including paravertebral blocks with 0.5% ropivacaine, celecoxib (400 mg po prior to surgery and 200 mg po bid for seven days), and ketamine (10 mg iv)
Number of subjects: 0
Study 21174182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic approach (MMA)
Number of subjects: 0
Study 21174182 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) alone
Number of subjects: 0
Study 18511476 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 585
Study 18511476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 585
Study 17154784 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended distractor features
Number of subjects: 0
Study 17154784 — intervention group
Group type: EXPERIMENTAL
Intervention: Response compatibility effect
Number of subjects: 0
Study 14526195 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspen TLSO
Number of subjects: 10
Study 14526195 — intervention group
Group type: COMPARATOR
Intervention: Boston Body Jacket
Number of subjects: 10
Study 14526195 — intervention group
Group type: COMPARATOR
Intervention: CAMP TLSO
Number of subjects: 10
Study 10896696 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A; Dysport)
Number of subjects: 40
Study 10896696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8716209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy
Number of subjects: 12
Study 7817261 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for exophytic warts or clinical symptoms (n = 55)
Number of subjects: 318
Study 7817261 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (n = 263; 150 with HPV suggestive lesions, 113 without)
Number of subjects: 318
Study 7817261 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use (anamnestic)
Number of subjects: 318
Study 7817261 — intervention group
Group type: EXPERIMENTAL
Intervention: ISH-positivity
Number of subjects: 318
Study 3061032 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (initial dose 50 mg/d)
Number of subjects: 50
Study 3061032 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (initial dose 80 mg/d)
Number of subjects: 50
Study 30563555 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 452
Study 30563555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 28052413 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Number of subjects: 511
Study 28052413 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose
Number of subjects: 511
Study 25497243 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T cardiovascular magnetic resonance-guided care
Number of subjects: 1200
Study 25497243 — intervention group
Group type: EXPERIMENTAL
Intervention: single-photon emission computed tomography-guided care
Number of subjects: 1200
Study 25497243 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institute for Health and Care Excellence guidelines-based management
Number of subjects: 1200
Study 25497243 — intervention group
Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 1200
Study 24321138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (PM1300 μg/m(3))
Number of subjects: 18
Study 24321138 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure (PM12 μg/m(3))
Number of subjects: 18
Study 20597264 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatological examination for RA diagnosis
Number of subjects: 3420
Study 20597264 — intervention group
Group type: COMPARATOR
Intervention: Self-reported RA diagnosis before examination
Number of subjects: 3420
Study 20597264 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis by specialist
Number of subjects: 3420
Study 20597264 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of RA diagnosis among identified patients
Number of subjects: 3420
Study 20597264 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of diagnosis in patients with less than one-year complaints
Number of subjects: 3420
Study 20597264 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of diagnosis in patients with long-term complaints
Number of subjects: 3420
Study 18203766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative long saphenous vein mapping (n=31)
Number of subjects: 61
Study 18203766 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 61
Study 16647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at doses of 50, 75, and 100 mg/day
Number of subjects: 47
Study 16647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from TPM and substitution with older antiepileptic drugs
Number of subjects: 47
Study 14521743 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphtoquine (1,000 mg single daily dosage for one day)
Number of subjects: 90
Study 14521743 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (750 mg single dosage)
Number of subjects: 90
Study 14521743 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (600 mg total dosage for five days, doubling dosage on the first day)
Number of subjects: 90
Study 10744189 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing out into water exercise during subtotal immersion (9 patients)
Number of subjects: 17
Study 10744189 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises without breathing out into water exercise (8 patients)
Number of subjects: 17
Study 8634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest (HCA)
Number of subjects: 0
Study 8634389 — intervention group
Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass (LFB)
Number of subjects: 0
Study 8634389 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA with longer duration
Number of subjects: 0
Study 8634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-stat strategy during cooling before HCA
Number of subjects: 0
Study 8634389 — intervention group
Group type: COMPARATOR
Intervention: pH-stat strategy
Number of subjects: 0
Study 1595791 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained residents providing brief structured smoking cessation advice
Number of subjects: 0
Study 1595791 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard advice
Number of subjects: 0
Study 6233176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) + Dexamethasone (DEX) 0.5 mg
Number of subjects: 64
Study 6233176 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg on days 5 to 9
Number of subjects: 64
Study 30808567 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 (pentavalent rotavirus vaccine)
Number of subjects: 4040
Study 30808567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4040
Study 30808567 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 (in concomitant use)
Number of subjects: 4040
Study 30808567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in concomitant use)
Number of subjects: 4040
Study 28875470 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP)
Number of subjects: 221
Study 26908117 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing style intervention
Number of subjects: 282
Study 26908117 — intervention group
Group type: COMPARATOR
Intervention: Mail-out recruitment strategy
Number of subjects: 282
Study 25110338 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative regression models
Number of subjects: 42839
Study 25110338 — intervention group
Group type: COMPARATOR
Intervention: Lowest-risk decile (mean STS-PROM of 0.6%)
Number of subjects: 42839
Study 25110338 — intervention group
Group type: COMPARATOR
Intervention: Highest-risk decile (mean STS-PROM 19%)
Number of subjects: 42839
Study 25110338 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 42839
Study 25110338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CABG procedure
Number of subjects: 42839
Study 22798531 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of mepivacaine 1.5% followed by 15 mL of bupivacaine 0.5% (group A)
Number of subjects: 64
Study 22798531 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of bupivacaine 0.5% followed by 15 mL of mepivacaine 1.5% (group B)
Number of subjects: 64
Study 21218459 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron on Days 1-5
Number of subjects: 143
Study 21218459 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron on Days 1, 3, and 5
Number of subjects: 143
Study 21218459 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 143
Study 17633481 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 42
Study 17633481 — intervention group
Group type: COMPARATOR
Intervention: Posterior fixation
Number of subjects: 42
Study 16242558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise rehabilitation (40% of maximal exercise capacity)
Number of subjects: 64
Study 16242558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise rehabilitation (80% of maximal exercise capacity)
Number of subjects: 64
Study 11933731 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10438706 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA+CT
Number of subjects: 413
Study 10438706 — intervention group
Group type: COMPARATOR
Intervention: ATRA-->CT
Number of subjects: 413
Study 10438706 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous maintenance CT
Number of subjects: 413
Study 10438706 — intervention group
Group type: COMPARATOR
Intervention: No CT
Number of subjects: 413
Study 10438706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ATRA
Number of subjects: 413
Study 10438706 — intervention group
Group type: COMPARATOR
Intervention: No ATRA
Number of subjects: 413
Study 10438706 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance CT
Number of subjects: 413
Study 10438706 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance ATRA
Number of subjects: 413
Study 7608278 — intervention group
Group type: EXPERIMENTAL
Intervention: iv dexamethasone (2.0‐16.0 mg/day)
Number of subjects: 12
Study 7608278 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 12
Study 7608278 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 12
Study 7608278 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone treatment
Number of subjects: 12
Study 2222952 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 10 mg extended release once daily
Number of subjects: 12
Study 2222952 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 2222952 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 12
Study 7446514 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 31707068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention exposure after randomisation
Number of subjects: 10
Study 28404834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mama SASHA intervention (enhanced nutrition counseling, community-based maternal support groups, vouchers for OFSP vine cuttings)
Number of subjects: 505
Study 28404834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mama SASHA intervention
Number of subjects: 505
Study 28404834 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinic-based nutrition counseling only)
Number of subjects: 505
Study 25690418 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day heat-stabilized rice bran (SRB) for 28 days
Number of subjects: 7
Study 22548586 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT followed by SRP
Number of subjects: 24
Study 22548586 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser followed by SRP
Number of subjects: 24
Study 22548586 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 24
Study 21327796 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 10 μg/min
Number of subjects: 23
Study 21327796 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 20 μg/min
Number of subjects: 23